Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.

Tacrolimus (FK506), an immunosuppressive drug, is co-medicated with multiple drugs under clinical conditions. Tacrolimus is highly lipophilic and is excreted from the body after receiving extensive metabolism. Due to its narrow therapeutic window following organ transplantation, tacrolimus requires therapeutic drug monitoring by an enzyme immunoassay using the monoclonal antibody raised against tacrolimus. Therefore, metabolism studies including drug-drug interaction and metabolite identification studies are essential for the efficient development and clinically optimal usage of this drug. Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine. Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism.

[1]  Kyungsoo Park,et al.  Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. , 2007, British journal of clinical pharmacology.

[2]  J. D. de Vries,et al.  Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate‐binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms , 2007, Fundamental & clinical pharmacology.

[3]  A. Takagi,et al.  [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor]. , 2006, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[4]  Satohiro Masuda,et al.  An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, Pharmacology & therapeutics.

[5]  M. Hebert,et al.  EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO , 2006, Drug Metabolism and Disposition.

[6]  T. Habuchi,et al.  Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.

[7]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[8]  B. Griffith,et al.  Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism , 2004, Journal of clinical pharmacology.

[9]  P. Beaune,et al.  Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 , 2003, Transplantation.

[10]  E. Schuetz,et al.  Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Y. Ohno,et al.  Oxidative Metabolism of Tacrolimus and its Metabolite by Human Cytochrome P450 3A Subfamily , 1999 .

[12]  R. M. Fisher,et al.  Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers , 1999, Journal of clinical pharmacology.

[13]  K. Iwasaki,et al.  Absorption, Distribution, Metabolism and Excretion of Tacrolimus(FK506) in the Rat. , 1998 .

[14]  T. Agishi,et al.  Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. , 1998, Transplantation proceedings.

[15]  F. Aweeka,et al.  The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy , 1996, Clinical pharmacokinetics.

[16]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[17]  K. Iwasaki,et al.  Comparison of Tacrolimus (FK506) Levels Determined by Three Different Methods in the Rat Blood , 1995 .

[18]  Y. Yamaoka,et al.  Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. , 1995, Transplantation proceedings.

[19]  H. Yamazaki,et al.  Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. , 1994, Biochemical pharmacology.

[20]  K. Iwasaki,et al.  Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. , 1993, Research communications in chemical pathology and pharmacology.

[21]  K. Iwasaki,et al.  Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[23]  S. Vincent,et al.  In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. , 1992, Archives of biochemistry and biophysics.

[24]  K. Iwasaki,et al.  Pharmacokinetic study of FK 506 in the rat. , 1991, Transplantation proceedings.

[25]  Mangan Kf.  Immunologic control of hemopoiesis: implications for quality of the graft after allogeneic bone marrow transplantation. , 1987 .

[26]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients , 2007, Clinical pharmacokinetics.

[27]  A. Daly.  Significance of the Minor Cytochrome P450 3A Isoforms , 2006, Clinical pharmacokinetics.

[28]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[29]  U. Christians,et al.  Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.

[30]  F. Guengerich,et al.  Interactions of FK506 (tacrolimus) with clinically important drugs. , 1996, Research communications in molecular pathology and pharmacology.

[31]  K. Iwasaki,et al.  Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. , 1995, Drug metabolism and disposition: the biological fate of chemicals.